Table 4.

Frontline cancer-directed treatment in curative (stages I, II, III) and metastatic (stage IV) lung cancer (N = 534).

	Asian (N = 118)		White (N = 416)
Frontline treatment	Curative (N = 47)	Metastatic (N = 71)	Curative (N = 254)	Metastatic (N = 162)
Chemoimmunotherapy	0 (0%)	7 (9.9%)	2 (0.8%)	12 (7.4%)
Chemoradiation	10 (21.3%)	6 (8.5%)	40 (15.7%)	14 (8.6%)
Chemotherapy	4 (8.5%)	13 (18.3%)	22 (8.7%)	40 (24.7%)
Immunotherapy	1 (2.1%)	6 (8.5%)	3 (1.2%)	5 (3.1%)
Radiation	3 (6.4%)	16 (22.5%)	23 (9.1%)	58 (35.8%)
Surgery	28 (59.6%)	5 (7.0%)	164 (64.6%)	24 (14.8%)
Targeted therapy	1 (2.1%)	18 (25.4%)	0 (0%)	9 (5.6%)